Mechanisms of B-cell lymphoma pathogenesis

Nature Reviews Cancer

Volumn 5, Issue 4, 2005, Pages 251-262

  Küppers, Ralf ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; B LYMPHOCYTE RECEPTOR; B7 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; CD86 ANTIGEN; CYCLIN D1; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; I KAPPA B ALPHA; IMMUNOGLOBULIN; MYC PROTEIN; PROTEIN BCL 10; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RETINOBLASTOMA PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR PAX5;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GENE MUTATION; GENE REARRANGEMENT; GERMINAL CENTER; HAIRY CELL LEUKEMIA; HELICOBACTER PYLORI; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTO ONCOGENE; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; SOMATIC HYPERMUTATION; TUMOR SUPPRESSOR GENE;

CELL COMMUNICATION; GENES, IMMUNOGLOBULIN; GENES, TUMOR SUPPRESSOR; GERMINAL CENTER; HUMANS; LYMPHOMA, B-CELL; MUTATION; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 16844381831     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1589     Document Type: Review

References (150)

1. Fisher, S. G. & Fisher, R. I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 23, 6524-6534 (2004).
2. Jaffe, E. S., Harris, N. L., Stein, H. & Vardiman, J. W. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues (eds Kleihuis, P. & Sobin, L.) (IARC, Lyon, 2001).
3. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
4. Küppers, R., Klein, U., Hansmann, M.-L. & Rajewsky, K. Cellular origin of human B-cell lymphomas. N. Engl. J. Med. 341, 1520-1529 (1999).
5. Stevenson, F. K. et al. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv. Cancer Res. 83, 81-116 (2001).
6. Greaves, M. F. Differentiation-linked leukemogenesis in lymphocytes. Science 234, 697-704 (1986).
7. Shatter, A. L., Rosenwald, A. & Staudt, L. M. Lymphoid malignancies: the dark side of B-cell differentiation. Nature Rev. Immunol. 2, 920-932 (2002).
8. Alizadeh, A. A. et al. Distinct types of diffuse large B-cel lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000). Showed that distinct subsets of diffuse large B-cell lymphoma can be identifed by large-scale gene-expression profiling.
9. Klein, U. et al. Gene expression profiling B cell chronic lymphocyte leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194, 1625-1638 (2001).
10. Küppers, R. & Dalla-Favera, R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20, 5580-5594 (2001).
11. Willis, T. G. & Dyer, M. J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96, 808-822 (2000).
12. Jäger, U. et al. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood 95, 3520-3529 (2000).
13. Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations invoked in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390-1393 (1985).
14. Tsujimoto, Y., Louie, E., Bashir, M. M. & Grace, C. M. The reciprocal partners of both the t(14;18) and the t(11;14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. Oncogene 2, 347-351 (1988).
15. Goossens, T., Klein, U. & Küppers, R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc. Natl Acad. Sci. USA 95, 2463-2468 (1998).
16. Brass, L. et al. DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. Immunity 13, 589-597 (2000).
17. Papavasiliou, F. N. & Schatz, D. G. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature 408, 216-221 (2000).
18. Pasqualucci, L, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341-346 (2001). Showed that multiple proto-oncogenes are targeted by somatic hypermutation specifically in diffuse large B-cell lymphomas, which could have a major role in the pathogenesis of this lymphoma.
19. Raghavan, S. C., Swanson, P. C., Wu, X., Hsieh, C. L. & Lieber, M. R. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428, 88-93 (2004).
20. Hlom, K., Melek, M. & Gellert, M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell 94, 463-470 (1998).
21. Roth, D. B. & Craig, N. L. VDJ recombination: a transposase goes to work. Cell 94, 411-414 (1998).
22. Müschen, M. et al. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J. Exp. Med. 192, 1833-1840 (2000).
23. Pasqualucci, L. et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc. Natl Acad. Sci. USA 95, 11816-11821 (1998).
24. Shen, H. M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750-1752 (1998).
25. Gronbaek, K. et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92, 3018-3024 (1998).
26. Esser, C. & Radbruch, A. Immunoglobulin class switching: molecular and cellular analysis. Annu. Rev. Immunol. 8, 717-735 (1990).
27. Küppers, R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nature Rev. Immunol 3, 801-812 (2003).
28. Rickinson, A. B. & Kieff, E. Epstein-Barr virus, in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2575-2627 (Lippincott-Raven, Philadelphia, 2001).
29. Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328-1337 (2004).
30. Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nature Rev. Cancer 4, 757-768 (2004).
31. Cannon, M. & Cesarman, E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin. Oncol. 27, 409-419 (2000).
32. Guasparri, I., Keller, S. A. & Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199, 993-1003 (2004).
33. Kraus, M., Alimzhanov, M. B., Rajewsky, N. & Rajewsky, K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 117, 787-800 (2004).
34. Lam, K. P., Kühn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073-1083 (1997). In references 33 and 34 mouse models were generated that provided strong evidence that normal mature B cells strictly depend on BCR expression and signalling for survival.
35. Gunven, P., Klein, G., Klein, E., Norin, T, & Singh, S. Surface immunoglobulins on Burkitt's lymphoma biopsy cells from 91 patients. Int. J. Cancer 25, 711-719 (1980).
36. Segal, G. H, et al. Concomitant delineation of surface Ig, B-cell differentiation antigens, and HLADR on lymphoid proliferations using three-color immunocytometry. Cytometry 12, 350-353 (1991).
37. Yano, T. et al. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 79, 1282-1290 (1992).
38. de Jong, D. et al. Translocation t(14;18) in B cell lymphomas as a cause for defective immunoglobulin production. J. Exp. Med. 169, 613-624 (1989).
39. Cleary M. L. et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 44, 97-106 (1986).
40. Meeker, T et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658-1665 (1985).
41. Braeuninger, A. et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc. Natl Acad. Sci. USA 94, 9337-9342 (1997).
42. Chapman, C. J., Mockridge, C. I., Rowe, M., Rickinson, A. B. & Stevenson, F. K. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 85, 2176-2181 (1995).
43. Losses, I. S. et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl Acad. Sci. USA 97, 10209-10213 (2000).
44. Thompsett, A. R., Ellison, D. W., Stevenson, F. K. & Zhu, D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94, 1738-1746 (1999).
45. Klein, U. et al. Somatic hypermutation in normal and transformed human B cells. Immunol. Rev. 162, 261-280 (1998).
46. Kanzler, H., Küppers, R., Hansmann, M. L. & Rajewsky, K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med. 184, 1495-1505 (1996). This study provided the first evidence that the tumour cells in Hodgkin's lymphoma are derived from 'crippled', BCR-deficient GC B cells
47. Küppers, R. Molecular biology of Hodgkin's lymphoma. Adv. Cancer Res. 84, 277-312 (2002).
48. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998).
49. Casola, S. et al. B cell receptor signal strength determines B cell fate. Nature Immunol. 5, 317-327 (2004). References 48 and 49 show that the EBV-encoded LMP2A can replace the function of the BCR in murine B cells.
50. Schwering, I. et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101, 1505-1512 (2003).
51. Engels, N. et al. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J. Exp. Med. 194, 255-264 (2001).
52. Merchant, M., Caldwell, R. G. & Longnecker, R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J. Virol. 74, 9115-9124 (2000).
53. Re, D. et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 61, 2080-2084 (2001).
54. Stein, H. et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97, 436-501 (2001).
55. Bräuninger, A. et al. Epstein-Barr virus (EBV)-positive lymphoproliferations in posttransplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur. J. Immunol. 33, 1593-1602 (2003).
56. Capello, D. et al. Molecular histogenesis of posttransplant lymphoproliferative disorders. Blood 102, 3775-3785 (2003).
57. Timms, J. M. et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 361, 217-223 (2003).
58. Leithäuser, F., Bäuerle, M., Huynh, M. Q. & Möller, P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 98, 2762-2770 (2001).
59. Pileri, S. A. et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am. J. Pathol. 162, 243-253 (2003).
60. Ritz, O. et al. Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line. J. Pathol. 205, 338-348 (2005).
61. Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862 (2003).
62. Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879 (2003).
63. Fais, F. et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia 13, 1093-1099 (1999).
64. Gaidano, G. & Carbone, A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. Adv. Cancer Res, 80, 115-146 (2001).
65. Matolcsy, A., Nador, R. G., Cesarman, E. & Knowles, D. M. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am. J. Pathol. 153, 1609-1614 (1998).
66. Arguello, M. et al. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22, 964-973 (2003).
67. Klein, U. et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101, 4115-4121 (2003).
68. Daneshek, W. & Schwartz, R. S. Leukemia and auto-immunization- some possible relationships. Blood 14, 1151-1158 (1959).
69. Borche, L., Lim, A., Binet, J. L. & Dighiero, G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 76, 562-569 (1990).
70. Sthoeger, Z. M. et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med. 169, 255-288 (1989).
71. Mann, D. L. et al. HTLV-1-associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science 236, 1103-1106 (1987).
72. Fais, F. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest 102, 1515-1525 (1998). References 72-75 show that B-CLL includes groups of cases with highly restricted BCR diversity, indicating a role of a set of common, restricted (auto)antigens in activating the lymphoma cells and/or their precursors.
73. Ghiotto, F, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J. Clin. Invest. 113, 1008-1016 (2004).
74. Messmer, B. T. et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med 200, 519-525 (2004).
75. Tobin, G. et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 101, 4952-4957 (2003).
76. Damle, R. N. et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99, 4087-4093 (2002).
77. Montesinos-Rongen, M. et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am. J. Pathol. 155, 2077-2086 (1999).
78. Dighiero, G. et al. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood 78, 581-585 (1991).
79. Bahler, D. W. & Levy, R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc. Natl Acad. Sci. USA 89, 6770-6774 (1992).
80. Zhu, D, et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99, 2562-2568 (2002).
81. Zhu, D., Ottensmeier, C. H., Du, M. Q., McCarthy H. & Stevenson, F. K. Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. Br. J. Haematol. 120, 217-222 (2003).
82. Quinn, E. R. et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98, 3745-3749 (2001).
83. Hermine, O. et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 347, 89-94 (2002).
84. Wotherspoon, A. C. et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 342, 575-577 (1993).
85. Hussel, T., Isaacson, P. G., Crabtree, J. E. & Spencer, J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J. Pathol. 178, 122-127 (1996). References 83-85 provide evidence that the growth of lymphoma cells might depend on chronic infection of the patients by bacteria or viruses.
86. Greiner, A. et al. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab. Invest. 70, 572-578 (1994).
87. Hussell, T., Isaacson, P. G., Crabtree, J. E., Dogan, A. & Spencer, J. Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am. J. Pathol. 142, 285-292 (1993).
88. Bende, R. J. et al. Immunoglobulins of B-cell non Hodgkin's lymphomas: musosa-associated lymphoid tissue lymphomas express a distinctive repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, (in the press).
89. Dogan, A. et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 91, 4708-4714 (1998).
90. Johnson, P. W. et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 82, 1848-1857 (1993).
91. + T cell dones. J. Immunol. 144, 2550-2557 (1990).
92. Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159-2169 (2004).
93. Schmid, C. & Isaacson, P. G. Proliferation centres in B-cell malignant lymphoma, lymphocyte (B-CLL): an immunophenotypic study. Histopathol. 24, 445-451 (1994).
94. Buske, C. et al. Stimulation of B-chronic lymphocyte leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp. Hematol. 25, 329-337 (1997).
95. Fluckiger, A. C. et al. Responsiveness of chronic lymphocytic leukemia B cells activated via surface lgs or CD40 to B-cell tropic factors. Blood 80, 3173-3181 (1992).
96. + T cells by producing CCL22. Eur. J. Immunol. 32, 1403-1413 (2002).
97. van den Berg, A., Visser, L. & Poppema, S. High expression of the CC chemokine TARC in Reed-Stemberg eels. A possible explanation for the characteristic T-cell infiltration Hodgkin's lymphoma. Am. J. Pathol. 154, 1685-1691 (1999).
98. Ehrenfeld, M., Abu-Shakra, M., Buskila, D. & Shoenfeld, Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol. Dis. 27, 750-756 (2001).
99. Straus, S. E. et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194-200 (2001).
100. Martin, T. et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 43, 908-916 (2000).
101. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
102. Küppers, R., Zhao, M., Hansmann, M. L. & Rajewsky, K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J. 12, 4955-4967 (1993).
103. MacLennan, I. C. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
104. Liu, Y. J. et al. Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Semin. Immunol. 8, 169-177 (1996).
105. Dogan, A. & Isaacson, P. G. Splenic marginal zone lymphoma. Semin. Diagn. Pathol. 20, 121-127 (2003).
106. Chiorazzi, N. & Ferrarini, M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21, 841-894 (2003).
107. Vaandrager, J. W. et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization Blood 88, 1177-1182 (196).
108. Camacho, E. et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99, 238-244 (2002).
109. Schaffner, C., Idler, I., Stilgenbauer, S., Dohner, H. Lichter, P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc. Natl Acad. Sci USA 97, 2773-2778 (2000).
110. Cuneo, A. et al. 13q14 deletion in non-Hodgkin's lymphoma: correlation with clinicopathologic features. Haematologica. 84, 589-593 (1999).
111. Schaffner, C., Stilgenbauer, S., Rappold, G. A., Döhner, H. & Lichter, P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94, 748-753 (1999).
112. Stankovic, T et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 353, 26-29 (1999).
113. Gaidano, G. et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88, 5413-5417 (1991).
114. Liu, Y. et al. 13q deletions in lymphoid malignancies. Blood 86, 1911-1915 (1995).
115. Baron, B. W. et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc. Natl Acad. Sci. USA 90, 5262-5266 (1993).
116. Ye, B. H., Rao, P. H., Chaganti, R. S. & Dalla-Favera, R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res, 53, 2732-2735 (1993).
117. Weiss, L. M., Warnke, R. A., Sklar, J. & Cleary, M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med. 317, 1185-1189 (1987).
118. Ladanyi, M., Offit, K., Jhanwar, S. C., Filippa, D. A. & Chaganti, R. S. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 77, 1057-1063 (1991).
119. Gronbaek, K. et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 100, 1430-1437 (2002).
120. Koduru, P. R. et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90, 4078-4091 (1997).
121. Moller, M. B. et al. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13, 453-459 (1999).
122. Melzner, I. et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line. Blood 105, 2535-2542 (2004).
123. Rossi, D. et al. Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. Blood 104, A2268 (2004).
124. Dalla-Favera, R., Martinotti, S., Gallo, R. C., Erikson, J. & Croce, C. M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219, 963-967 (1983).
125. Taub, R. et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79, 7837-7841 (1982).
126. Cinti, C. et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am. J. Pathol. 156, 751-760 (2000).
127. Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F. & Hay, R. T. Mutations in the IκBαgene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 18, 3063-3070 (1999).
128. Krappmann, D. et al. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18, 943-953 (1999).
129. Jungnickel, B. et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's disease. J. Exp. Med. 191, 395-401 (2000).
130. Emmerich, F. et al. Inactivating IκBε mutations in Hodgkin/Reed-Sternberg cells. J. Pathol. 201, 413-420 (2003).
131. Muschen, M. et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 60, 5640-5643 (2000).
132. Martin-Subero, J. I. et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Bleed 99, 1474-1477 (2002).
133. Wlodarska, I. et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 101, 706-710 (2003).
134. Mateo, M. et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am. J. Pathol. 154, 1583-1589 (1999).
135. Dierlamm, J. et al. The apoptosis inhibitor gene AP/2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601-3609 (1999).
136. Willis, T. G. et al. Bcl10 is involved in t(1;14)(p22:q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96, 35-45 (1999).
137. Zhang, Q. et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nature Genet. 22, 63-68 (1999).
138. Streubel, B. et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101, 2335-2339 (2003).
139. Streubel, B., Vinatzer, U., Lamprecht, A., Raderer, M. & Chott, A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 10 Feb 2005 (doi:10.1038/sj.leu.2403644).
140. Bertoni, F. et al. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. Leukemia 14, 446-448 (2000).
141. Seeberger, H. et al. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab. Invest. 81, 977-986 (2001).
142. Iida, S. et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Stood 88, 4110-4117 (1996).
143. Nador, R. G. et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88, 645-656 (1996).
144. Avet-Loiseau, H. et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 58, 5640-5645 (1998).
145. Chesi, M. et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet. 16, 260-264 (1997).
146. Chesi, M. et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91, 4457-4463 (1998).
147. Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S. & Dalton, W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266-4270 (1997).
148. Shou, Y. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl Acad. Sci. USA 97, 228-233 (2000).
149. Liu, P. et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88, 2699-2706 (1996).
150. Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nature Rev. Cancer 2, 175-187 (2002).